BW-20829 / Argo Biopharma - LARVOL DELTA

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=64 | Suspended | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Suspended

Trial suspension

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=64 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | N=40 ➔ 64

Enrollment change

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=40 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023

Enrollment open • Trial initiation date